⌘K

07:01:40·1d

SECFilingvia Quantisnow

NovoCure Limited filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

ByQuantisnow·Wall Street's wire, on your screen.

NVCR· NovoCure Limited

Health Care

Original source

Quantisnowquantisnow.com

Quantisnow streams SEC filings, FDA approvals, analyst ratings, insider trades, and press releases to retail investors in real time. This insight was curated and delivered from the Quantisnow live feed.

Companies

NVCR
NovoCure Limited
Health Care

Recent analyst ratings

Jul 25UpdateWells Fargo$14.50
Jul 8UpdateLadenburg Thalmann$30.00
Dec 2UpdateEvercore ISI$30.00
Oct 16UpdateH.C. Wainwright$30.00
Nov 20UpdateJP Morgan$15.00
Aug 28UpdateH.C. Wainwright$25.00

Related

SEC1d
SEC Form 10-Q filed by NovoCure Limited
PR1d
Novocure Reports First Quarter 2026 Financial Results
INSIDER3d
Director Vernon W Anthony exercised 21,500 units of Ordinary Shares at a strike of $11.39, increasing direct ownership by 12% to 200,602 units (SEC Form 4)
SEC7d
Amendment: NovoCure Limited filed SEC Form 8-K: Leadership Update, Financial Statements and Exhibits
SEC11d
SEC Form DEFA14A filed by NovoCure Limited
SEC11d
SEC Form DEF 14A filed by NovoCure Limited
SEC22d
NovoCure Limited filed SEC Form 8-K: Leadership Update, Financial Statements and Exhibits
PR30d
Novocure to Report First Quarter 2026 Financial Results